1. Introduction {#sec1-cancers-11-01505}
===============

Pheochromocytomas/paragangliomas (PCCs/PGLs) are rare neuroendocrine tumors, mostly catecholamine-producing and originating from chromaffin tissue derived from the neural crest. The incidence of diagnosed PCC/PGL is about 0.8/100,000 patients/year \[[@B1-cancers-11-01505]\] with around 30--40% being hereditary and another 40--50% of patients showing identifiable somatic mutations in many of the currently identified 20 PCC/PGL susceptibility genes \[[@B2-cancers-11-01505],[@B3-cancers-11-01505]\]. However, the incidence may be underestimated, since earlier studies showed that 50% of PCCs/PGLs found at autopsy were not clinically suspected or diagnosed \[[@B4-cancers-11-01505]\].

The mean age of PCC/PGL diagnosis is the fourth and fifth decade, although 10--20% of all cases are diagnosed in children \[[@B5-cancers-11-01505]\]. Patients with known mutations in susceptibility genes tend to develop PCC/PGL at a younger age, compared with patients with sporadic tumors, in part because of biochemical and/or anatomic surveillance.

PCCs arise from the adrenal medulla; PGLs are extra-adrenal and originate from the sympathetic paraganglia (85% arise below the diaphragm) or from the parasympathetic paraganglia (head-and-neck paragangliomas). All PGLs arising from the parasympathetic ganglia are denoted as head-and-neck (HN) PGLs, although they may also arise from the anterior and middle mediastinum along the vagus nerve. Over 95% of HN PGLs are non-functioning and do not overproduce noradrenalin, although a small number (1--3%) of HN PGLs can overproduce it. PCCs and PGLs may produce adrenalin (epinephrine), noradrenalin (norepinephrine), or dopamine in varying proportions, depending on adrenal versus extra-adrenal location and the underlying gene mutation as well as developmental background (sympathetic vs. parasympathetic).

Measurement of free metanephrine, normetanephrine, and 3-methoxytyramine---the respective O-methylated metabolites of epinephrine, norepinephrine, and dopamine---provides currently the best recommended plasma test whereas measurement of the two first metabolites, preferably in the free form but also after acid hydrolysis as deconjugated metabolites, provides recommended urinary tests for PCC/PGL diagnosis \[[@B6-cancers-11-01505]\] with recent evidence of the slight superiority of the plasma over urinary tests \[[@B6-cancers-11-01505]\]. However, 3-methoxytyramine may not be available in the United States and other countries in commercial laboratories, although its assessment is recommended, where possible. Tumoral secretion of catecholamines leads to signs and symptoms of migraine-like headache, sweating, palpitations, episodic or sustained hypertension, anxiety, tremor, nausea, weakness, pallor, weight loss, or postural hypotension. These features are, however, non-specific, and vary according to tumoral catecholamine production, content, and secretion; this can be independent of tumor size, explaining why some similarly-sized tumors produce symptoms while others do not \[[@B7-cancers-11-01505]\]. Yet, in intra-patient comparisons, increase of tumor diameter and tumor burden correlates with the increase in plasma and urinary metanephrines but less accurately with urinary catecholamines \[[@B8-cancers-11-01505]\]. Very rarely, PCCs/PGLs may be non-functional and synthesize no or only negligible catecholamines reaching a large size before diagnosis, usually due to their mass effect \[[@B9-cancers-11-01505]\]; however, most cases of PCCs/PGLs with negative test results for plasma O-methylated metabolites reflect small tumors or metastatic disease with some degree of cell dedifferentiation \[[@B6-cancers-11-01505]\].

About 10% of PCCs and a significantly higher proportion---35--40%---of PGLs are metastatic, especially those due to mutations of the succinate dehydrogenase A/B (*SDHA/B*) gene \[[@B10-cancers-11-01505],[@B11-cancers-11-01505],[@B12-cancers-11-01505],[@B13-cancers-11-01505],[@B14-cancers-11-01505],[@B15-cancers-11-01505],[@B16-cancers-11-01505],[@B17-cancers-11-01505]\]. The median five-year survival rate of metastatic patients is around 60--70% but this differs according to the populations studied \[[@B18-cancers-11-01505]\]. Malignancy is defined by the presence of distant metastases at sites where chromaffin cells are normally absent---bones and lymph nodes \[[@B19-cancers-11-01505]\]. However, for lung and liver, it has to be considered that both organs normally contain ganglia, and therefore in these locations, it may be difficult to differentiate between metastases and primary PGLs, especially if past medical history is negative \[[@B20-cancers-11-01505],[@B21-cancers-11-01505],[@B22-cancers-11-01505],[@B23-cancers-11-01505],[@B24-cancers-11-01505],[@B25-cancers-11-01505]\]. Validated prognostic pathological parameters for malignant PCCs/PGLs are lacking, although some risk stratification systems have been described, such as *The Pheochromocytoma of the Adrenal Gland Scaled Score* (PASS) \[[@B26-cancers-11-01505]\] and the more recently extended *Grading of Adrenal Pheochromocytoma and Paraganglioma* (GAPP) \[[@B27-cancers-11-01505]\]. However, as reviewed \[[@B28-cancers-11-01505]\], these score systems have limited predictive ability. Nevertheless, the 'rule-out' value of both algorithms seems promising in order to exclude future metastatic potential: PCCs with a PASS score \<4 and PCCs/PGLs with a GAPP score \<3 are exceedingly seldom malignant \[[@B29-cancers-11-01505]\].

In the most recent American Joint Committee of Cancer Staging (AJCC) guidelines a novel TNM staging for PCC/PGL was introduced, and clinical relevance has recently been validated retrospectively with PCCs and sympathetic PGLs in stage III--IV (regional lymph node metastases or invasion into surrounding tissue or distant metastases) being associated with increased PASS/GAPP scores and increased mortality, as well as aberrations in the pseudo-hypoxia pathway cluster \[[@B30-cancers-11-01505],[@B31-cancers-11-01505]\].

Moreover, there are some predictors associated with a higher likelihood of metastatic disease. These include size (≥5--6 cm), extra-adrenal location of the primary tumor, noradrenergic/dopaminergic biochemical phenotype, mutations of the succinate dehydrogenase A and B (*SDHA/B*) genes, tumor multiplicity/recurrence, and age at first presentation (\<20 years) \[[@B5-cancers-11-01505],[@B17-cancers-11-01505]\]. This review summarizes the more recent findings concerning biomarkers and their application in a clinical setting, up-to-date imaging modalities, follow-up recommendations for apparently sporadic and hereditary PCC/PGLs, and therapeutic approaches including surgery and treatments for malignancy.

2. Genetics {#sec2-cancers-11-01505}
===========

Around 30--40% of PCC/PGL patients show identifiable germline and another 46% somatic mutations in at least 20 known susceptibility genes \[[@B2-cancers-11-01505],[@B32-cancers-11-01505],[@B33-cancers-11-01505]\]. This means that around three-quarters of all PCC/PGL patients can be assigned to one of the three molecular clusters (as recently reviewed \[[@B33-cancers-11-01505],[@B34-cancers-11-01505]\]).

2.1. Cluster 1: Pseudohypoxic Krebs Cycle-Related Genes and Pseudohypoxia VHL/EPAS1-Related Genes {#sec2dot1-cancers-11-01505}
-------------------------------------------------------------------------------------------------

**Cluster 1 pseudohypoxic Krebs cycle-related genes**: genes encoding succinate dehydrogenase subunits (*SDHx \[SDHA, SDHB, SDHC, SDHD\]*), succinate dehydrogenase complex assembly factor-2 (*SDHAF2*), fumarate hydratase (*FH*), malate dehydrogenase 2 (*MDH2*), and isocitrate dehydrogenase 1 (*IDH1*); **cluster 1 pseudohypoxia *VHL/EPAS1*-related genes:** Egl-9 prolyl hydroxylase-1 and -2 (*PHD1/2*), von Hippel--Lindau tumor suppressor (*VHL*) and hypoxia-inducible factor 2α (*HIF2A/EPAS1/2*).

Cluster 1 is called pseudohypoxic since it mimics cellular hypoxia: The Krebs cycle is disrupted due to mutations in several genes (*SDHA\[AF2\]/B/C/D, FH, MDH2*, and *IDH*) and, therefore, the Krebs cycle and oxidative phosphorylation are impaired resulting in increased cellular glycolysis. This in turn leads to accumulation of the oncometabolites succinate, fumarate, or 2-hydroxyglutarate which favors DNA hypermethylation and inactivation of different tumor suppressor genes, including *PHD1/2*, as previously reviewed \[[@B35-cancers-11-01505]\]. Inactivation of *PHD1/2* results in less HIF-α hydroxylation and less HIF-α ubiquitination/degradation (HIF-α is stabilized), which is also VHL-dependent; thus, *VHL* mutations also lead to HIF-α stabilization and accumulation. Via HIF-α stabilization and accumulation, cluster 1 mutations promote angiogenesis (VEGF/PDGF transcription amongst others), tumor invasion, metastasis and other cellular processes. HIF-α is the confluent of cluster 1 mutations, and interconnects cluster 1 with cluster 2 mutations \[[@B36-cancers-11-01505]\]. PCCs/PGLs resulting especially from mutations in Krebs cycle enzyme *SDHx* subunits are often multiple, aggressive, metastatic, and have a poorer prognosis, compared to PCCs/PGLs bearing other susceptibility gene mutations, especially those related to cluster 2 \[[@B37-cancers-11-01505]\]. Cluster 1 mutations can be subdivided in pseudohypoxic Krebs cycle-related and pseudohypoxia *VHL/EPAS1*-related PCCs/PGLs (see above). Almost all tumors belonging to this cluster have a noradrenergic biochemical phenotype and produce noradrenalin (measured metabolite: normetanephrine), and/or dopamine (measured metabolite: 3-methoxytyramine), but no adrenalin (measured metabolite: metanephrine).

2.2. Cluster 2: Kinase Signaling-Related Genes {#sec2dot2-cancers-11-01505}
----------------------------------------------

Genes belonging to cluster 2 are the rearranged-during-transfection (*RET*) proto-oncogene, neurofibromin 1 (*NF1*) tumor suppressor, *HRAS*, transmembrane protein 127 (*TMEM127*), and Myc-associated factor X (*MAX*). These mutations lead to activation of the phosphatidylinositol-3-kinase (PI3K)/AKT, mammalian target of rapamycin (mTORC1)/p70S6 kinase (p70S6K), and RAS/RAF/ERK signaling pathway and promote cell proliferation, survival, cancer development, and angiogenesis. Most of the cluster 2 mutations lead to an adrenergic biochemical phenotype with production of adrenalin (measured metabolite: metanephrine) +/− noradrenalin (measured metabolite: normetanephrine). *Max* mutations are most likely to show an intermediate biochemical phenotype \[[@B38-cancers-11-01505]\].

2.3. Cluster 3: Wnt Signaling-Related Genes {#sec2dot3-cancers-11-01505}
-------------------------------------------

The Cold Shock Domain-containing E1 gene (*CSDE1*) and the 'mastermind-like' transcriptional coactivator 3 (*MAML3*) fusion genes belong to cluster 3 \[[@B2-cancers-11-01505]\]. *MAML3* mutations lead to overactivation of Wnt and Hedgehog signaling. These tumors strongly express chromogranin A. *CSDE1* mutations lead to over-activation of β-catenin, a target of Wnt signaling, and favor tumor proliferation, invasion, and metastases. The catecholamine phenotype is not known. *MAML3*-mutated PCCs/PGLs showed high Ki-67 expression, aggressive behavior, and early metastatic spread \[[@B2-cancers-11-01505]\].

2.4. Summary: Cluster 1, 2 and 3 {#sec2dot4-cancers-11-01505}
--------------------------------

Knowledge about how a particular patient may be assigned to one of these clusters can guide biochemical testing, specific imaging modalities, and appropriate personalized treatments ([Table 1](#cancers-11-01505-t001){ref-type="table"}) \[[@B32-cancers-11-01505]\].

This further justifies subjecting all PCC/PGL patients to genetic testing for germline mutations \[[@B39-cancers-11-01505]\].

Somatic tumor mutations may indeed also influence prognosis, since different somatic mutations correlate with different metastatic risks in a similar manner as germline mutations do ([Table 1](#cancers-11-01505-t001){ref-type="table"}), although, of course, this is still the subject of ongoing research. Moreover, a personalized molecular-targeted therapy approach could result from somatic mutations such as *RET, NF1, HRAS, MAX, TMEM127*, or those of defective pseudohypoxia signaling, much as it does from the molecular testing in other cancer entities such as differentiated thyroid carcinoma, bronchial carcinoma, or breast cancer \[[@B40-cancers-11-01505],[@B41-cancers-11-01505]\].

### Conclusion/Practical Tips

We recommend genetic testing for germline mutations for *all* PCC/PGL patients; testing of tumor material, where available, for somatic tumor mutation analysis can also provide useful additional information.

3. Diagnosis {#sec3-cancers-11-01505}
============

3.1. Biochemistry {#sec3dot1-cancers-11-01505}
-----------------

Measurements of plasma free or urinary metanephrines are the recommended screening tests for the biochemical diagnosis of PCC/PGL \[[@B42-cancers-11-01505]\], with recent evidence now establishing the superiority of the plasma over urinary tests \[[@B6-cancers-11-01505]\]. However, high accuracy of the plasma test can only be assured using appropriately established measurement methods and reference intervals, combined with correctly applied preanalytics, especially sampling of blood in the supine position \[[@B6-cancers-11-01505],[@B43-cancers-11-01505],[@B44-cancers-11-01505],[@B45-cancers-11-01505]\]. Under these conditions, plasma concentrations of normetanephrine, metanephrine, or methoxytyramine more than two-fold above upper cut-offs of reference intervals indicate a high probability of PCC/PGL even at low pre-test prevalence of disease \[[@B8-cancers-11-01505],[@B46-cancers-11-01505]\]. Combined increases of two or more metabolites also suggest a high probability of PCC/PGL. In other cases, intra-patient longitudinal comparisons can be useful to confirm progression of disease (i.e. increased disease burden), which in most cases is slow and involves a doubling-time of over two years \[[@B8-cancers-11-01505]\]. Biochemical testing for PCC/PGL in patients screened due to signs and symptoms of apparent catecholamine excess should always be performed before imaging \[[@B42-cancers-11-01505]\]. Moreover, it is important to instruct the patients to abstain from caffeine, black tea, nicotine, alcohol, bananas, cheese, almonds, nuts, chocolate, eggs, or vanilla three days prior to assessment of plasma free or urine metanephrines. Tricyclic antidepressants, serotonin re-uptake inhibitors, ephedrine, cocaine, and metamphetamine may lead to false positive results.

As shown in [Table 1](#cancers-11-01505-t001){ref-type="table"}, pseudohypoxic cluster 1 type PCC/PGL are linked to a noradrenergic (predominantly increased normetanephrine) phenotype because the tumors lack the enzyme, phenylethanolamine N-methyl transferase (PNMT), which converts noradrenalin to adrenalin \[[@B47-cancers-11-01505],[@B48-cancers-11-01505]\]. Moreover, a substantial proportion of PCCs/PGLs in *SDHx* mutation carriers also appear to show some additional deficiency in the enzyme dopamine-β-hydroxylase, which catalyzes the final step in catecholamine synthesis---the conversion of dopamine to noradrenalin; patients with such tumors show increased production of the dopamine metabolite 3-methoxytyramine \[[@B8-cancers-11-01505],[@B49-cancers-11-01505],[@B50-cancers-11-01505]\]. Thus, all cluster 1 PCCs/PGLs may be diagnosed by elevated normetanephrine levels, with or without increases in 3-methoxytyramine. However, measurements of urinary 3-methoxytyramine are *not* useful and only plasma 3-methoxytyramine is of significant diagnostic utility \[[@B6-cancers-11-01505]\]. Moreover, *SDHx* mutation carriers often show reduced synthesis and secretion of normetanephrine and in rare cases lack the initial rate-limiting enzyme of catecholamine synthesis (tyrosine hydroxylase); such cases may be termed non-functional or biochemically silent \[[@B9-cancers-11-01505]\]. *SDHx* mutation carriers can therefore be diagnosed preferentially by normetanephrine and 3-methoxytyramine while, in cases of silent phenotypes, circulating chromogranin A may be a useful marker \[[@B51-cancers-11-01505],[@B52-cancers-11-01505],[@B53-cancers-11-01505]\]. It is important to note that there are multiple other diseases, conditions, and medications leading to false positive chromogranin A results. Diseases potentially leading to elevated chromogranin A levels are other endocrine diseases/tumors (pulmonary/gastrointestinal neuroendocrine tumors, medullary thyroid carcinomas, pituitary tumors, hyperthyroidism, hyperparathyroidism, small cell lung cancer, prostate cancer, breast cancer, ovary carcinoma), systemic inflammatory diseases (systemic rheumatoid arthritis, chronic bronchitis, chronic airway obstruction in smokers), renal insufficiency, gastrointestinal disorders (chronic atrophic gastritis, pancreatitis, inflammatory bowel disease, irritable bowel syndrome, liver cirrhosis, chronic hepatitis, hepatocellular carcinoma, pancreatic and colon cancer), cardiovascular diseases (arterial hypertension, cardiac insufficiency, acute coronary syndrome), drugs (proton pump inhibitors, H2 blockers, steroids), and pregnancy. Therefore, it is especially important to instruct the patient to withhold proton pump inhibitors for at least one week, optimally for two to three weeks, prior to assessment of chromogranin A. H2 blockers should be withheld at least two days prior to chromogranin A assessment if possible.

Since biochemical testing may not be applicable in patients with non-functioning PCC/PGL, clinicians have to rely on repeat imaging for surveillance.

Patients with chromaffin cell tumors due to cluster 2 mutations are usually diagnosed by elevations in both normetanephrine and metanephrine or only metanephrine \[[@B47-cancers-11-01505],[@B54-cancers-11-01505],[@B55-cancers-11-01505]\].

### Conclusion/Practical Tips

Measurements of plasma free normetanephrine, metanephrine, and 3-methoxytyramine, or urinary normetanephrine and metanephrine, are the recommended biochemical tests for PCC/PGL screening and follow-up \[[@B39-cancers-11-01505],[@B54-cancers-11-01505],[@B56-cancers-11-01505],[@B57-cancers-11-01505],[@B58-cancers-11-01505]\] (no caffeine, black tea, nicotine, alcohol, bananas, cheese, almonds, nuts, chocolate, eggs, or vanilla three days prior to assessment).

Especially in the case of a history/suspicion of PGLs, metastatic disease or in *SDHx* mutation carriers, additional assessments of plasma 3-methoxytyramine (but not urinary 3-methoxytyramine) are useful \[[@B17-cancers-11-01505]\] since highly elevated 3-methoxytyramine levels may suggest the presence of metastatic tumors \[[@B9-cancers-11-01505],[@B17-cancers-11-01505]\]. Such patients may be triaged for pre-operative staging (if possible by radionuclide imaging, see below) \[[@B39-cancers-11-01505]\].

In the case of a suspected or diagnosed non-functional PGL/PCC, chromogranin A should be measured (no proton pump inhibitor at least one week prior to assessment).

3.2. Imaging for Diagnosis, Staging, and Follow-Up {#sec3dot2-cancers-11-01505}
--------------------------------------------------

For the localization of adrenal PCCs, anatomic imaging with magnetic resonance imaging (MRI) or computed tomography (CT) has almost 100% sensitivity \[[@B42-cancers-11-01505],[@B59-cancers-11-01505],[@B60-cancers-11-01505]\]. However, for *SDHx* mutated PGLs, HN PGLs, metastatic disease, and small, multiple PCCs/PGLs, both CT/MRI and meta-\[^123^I\]iodobenzylguanidine (\[^123^I\]MIBG) single-photon emission computed tomography (SPECT) suffer from significantly lower sensitivity compared to more recent radionuclide imaging \[[@B59-cancers-11-01505],[@B61-cancers-11-01505],[@B62-cancers-11-01505]\].

A recent meta-analysis of pooled PCC/PGL detection by radionuclide imaging showed the highest sensitivity (93%) for ^68^Gallium-labeled somatostatin receptor analogs (SSAs) positron emission tomography/computed tomography (\[^68^Ga\]Ga-DOTA-SSA PET/CT), the second highest sensitivity for dihydroxy-\[^18^F\]fluorophenylalanine (\[^18^F\]FDOPA) PET/CT (80%), and the lowest sensitivity for \[^18^F\]fluorodeoxyglucose (\[^18^F\]FDG) PET/CT (74%) \[[@B63-cancers-11-01505]\].

However, in order to choose the imaging modality with the highest sensitivity, it is important to consider that different sub-groups of PCC/PGL patients show different sensitivities to \[^68^Ga\]Ga-DOTA-SSAs, \[^18^F\]FDOPA, and \[^18^F\]FDG PET/CT, respectively. The sensitivities to the different imaging modalities depend on the presence of PGL versus PCC, HN PGLs, sporadic metastatic, or non-metastatic disease, cluster 1 Krebs cycle-related *SDHx* mutations and *VHL/EPAS1* pseudohypoxia-related mutations or cluster 2 kinase signaling-associated mutations ([Table 2](#cancers-11-01505-t002){ref-type="table"}) \[[@B64-cancers-11-01505]\].

Highest lesion-based diagnostic sensitivity of \[^68^Ga\]Ga-DOTA-SSA PET/CT has been found for the following disease characteristics ([Table 2](#cancers-11-01505-t002){ref-type="table"}):(1)Metastatic *SDHB*-related PCCs/PGLs (\[^68^Ga\]Ga-DOTA-SSA 99% vs. \[^18^F\]FDOPA 61% vs. \[^18^F\]FDG PET/CT 86%) \[[@B61-cancers-11-01505]\];(2)*SDHA*-related PCCs/PGLs (highest lesion detection sensitivity: \[^68^Ga\]Ga-DOTA-SSA \> \[^18^F\]FDG \> \[^18^F\]FDOPA PET/CT) \[[@B65-cancers-11-01505]\];(3)*SDHD*-related PCCs/PGLs (\[^68^Ga\]Ga-DOTA-SSA 99% vs. \[^18^F\]FDOPA 87% vs. \[^18^F\]FDG PET/CT 62%) \[[@B66-cancers-11-01505]\];(4)Pediatric *SDHx*-related PGLs/PCCs (\[^68^Ga\]Ga-DOTA-SSA 94% vs. \[^18^F\]FDG PET/CT 79%) \[[@B67-cancers-11-01505]\];(5)HN PGLs (frequently *SDHD*-related) (\[^68^Ga\]Ga-DOTA-SSA 100% vs. \[^18^F\]FDOPA 97% vs. \[^18^F\]FDG PET/CT 71%) \[[@B68-cancers-11-01505],[@B69-cancers-11-01505]\];(6)PGLs \[pooled lesion-based sensitivity of \[^68^Ga\]Ga-DOTA-SSA PET/CT was higher, compared to \[^18^F\]FDOPA PET/CT in two different studies (\[^68^Ga\]Ga-DOTA-SSA 99% and 100% vs. \[^18^F\]FDOPA PET/CT 68% and 71%, respectively)\] \[[@B69-cancers-11-01505],[@B70-cancers-11-01505]\];(7)Sporadic metastatic PCCs/PGLs (\[^68^Ga\]Ga-DOTA-SSA 98% vs. \[^18^F\]FDOPA 75% vs. \[^18^F\]FDG PET/CT 49%) \[[@B71-cancers-11-01505]\].

A higher lesion-based sensitivity of \[^18^F\]FDOPA, compared to \[^68^Ga\]Ga-DOTA-SSA, has been shown for the following disease characteristics ([Table 2](#cancers-11-01505-t002){ref-type="table"}):(1)(Sporadic) PCCs (\[^18^F\]FDOPA 94% vs. \[^68^Ga\]Ga-DOTA-SSA PET/CT 81%) \[[@B69-cancers-11-01505]\];(2)Moreover, for *EPAS1 (HIF2A)*-, *PHD1/2-*, *FH-*, and *MAX*-related PGLs, \[^18^F\]FDOPA PET/CT seems to be the imaging modality with the highest lesion-based sensitivity (for *MAX*-related PCCs/PGLs \[^18^F\]FDOPA 91% vs. \[^68^Ga\]Ga-DOTA-SSA 57% vs. \[^18^F\]FDG PET/CT 18%) although these findings have to be confirmed in a larger patient group with *FH* mutations \[[@B72-cancers-11-01505],[@B73-cancers-11-01505],[@B74-cancers-11-01505],[@B75-cancers-11-01505]\];(3)*VHL*-related PGLs/PCCs belong to the pseudohypoxia group without leading to succinate accumulation and show high \[^18^F\]FDOPA uptake but variable \[^18^F\]FDG uptake which probably makes \[^18^F\]FDOPA PET/CT the most sensitive imaging modality in *VHL*-related PCCs/PGLs;(4)In the kinase signaling group, \[^18^F\]FDOPA also seems to be the most sensitive radiopharmaceutical due to high uptake by the tumor and low uptake in the remaining adrenal gland; however, a head-to-head comparison with \[^68^Ga\]Ga-DOTA-SSA and \[^18^F\]FDG PET/CT has only been performed for *MAX*-related PCCs/PGLs as yet \[[@B74-cancers-11-01505]\].

### Conclusion/Practical Tips

For PCC screening in the case of elevated metanephrines, CT (or MRI in young patients) should usually be sufficient.

However, in *all* patients with PCC/PGL (except for patients with low risk of metastatic disease, i.e., epinephrine secreting PCC \<3--5 cm), whole-body CT or MRI or radionuclide imaging is recommended prior to surgery in order to rule out metastatic disease/multiplicity which may affect the decision regarding surgery \[[@B39-cancers-11-01505]\].

For HN PGLs, sporadic sympathetic PGLs, metastatic tumors, and *SDHx*-related PCCs/PGLs \[[@B76-cancers-11-01505]\], \[^68^Ga\]Ga-DOTA-SSA PET/CT should be the first choice radionuclide imaging for diagnosis, staging, and follow-up ([Table 1](#cancers-11-01505-t001){ref-type="table"} and [Table 2](#cancers-11-01505-t002){ref-type="table"}). Another advantage of \[^68^Ga\]Ga-DOTA-SSA PET/CT is its predictive power for the efficacy of peptide receptor radionuclide therapy (PRRT) (see below). If \[^68^Ga\]Ga-DOTA-SSA PET/CT is not available, for *SDHx*-related PCCs/PGLs, \[^18^F\]FDG PET/CT should be the second choice; however, for non-*SDHx*-related PGLs and (*SDHD*-related) HN-PGLs \[^18^F\]FDOPA should be the second choice ([Table 2](#cancers-11-01505-t002){ref-type="table"}).

In contrast, for (sporadic) PCCs, *VHL, HIF2A*, and kinase signaling-associated (*RET, NF1, MAX*) PCCs/PGLs \[^18^F\]FDOPA PET/CT should be the first choice radionuclide imaging for diagnosis, staging, and follow-up ([Table 1](#cancers-11-01505-t001){ref-type="table"} and [Table 2](#cancers-11-01505-t002){ref-type="table"}); if not available \[^68^Ga\]Ga-DOTA-SSA PET/CT should be the second choice except for *HIF2A* and *PHD1/2.* For *HIF2A* and *PHD1/2* \[^18^F\]FDG PET/CT should be the preferred second choice ([Table 2](#cancers-11-01505-t002){ref-type="table"}).

3.3. Biopsy Is Not Recommended {#sec3dot3-cancers-11-01505}
------------------------------

There is no recommendation for performing biopsy in PCCs/PGLs. The European guideline for adrenal incidentalomas \[[@B77-cancers-11-01505]\] claims that biopsy of an adrenal tumor should only be performed if: ○There is another extra-adrenal malignancy in the patient's history;○The tumor is non-functioning (especially non-functioning PCCs/PGLs);○Not judged as benign on imaging;○Biopsy would change patient management.

Therefore, biopsy should only be considered in special cases of non-functioning potential PCCs/PGLs when all biochemistry is negative and it would change patient management, for example, due to another extra-adrenal malignancy in the patient's history. Otherwise, the adrenal mass should generally be surgically resected due to the risk of a catastrophic complication related to a biopsy of a functioning PCC/PGL \[[@B78-cancers-11-01505]\].

### Conclusion/Practical Tips

We strongly discourage image-guided biopsy of any adrenal or suspicious retroperitoneal mass without pre-biopsy biochemical case detection testing.

3.4. Immunohistochemistry: Biomarkers {#sec3dot4-cancers-11-01505}
-------------------------------------

Besides typical morphology, well-known biomarkers for PCC/PGLs are positive immunohistochemistry for chromogranin A, synaptophysin, and S100; however, this does not allow differentiation from any other neuroendocrine tumors. This in turn may be a problem if the patient does not show a typical clinical presentation or biochemistry for a PCC/PGL. In these cases, negativity for keratin and site-specific transcription factors for neuroendocrine tumors as well as positivity for tyrosine hydroxylase (except for non-functioning HN PGLs) and GATA-3 immunohistochemistry seem to be valuable biomarkers to confirm the diagnosis of a PCC/PGL in most cases, as recently reviewed \[[@B20-cancers-11-01505]\]. Future potential relevant biomarkers suggesting metastatic potential may be TERT structural variants \[[@B79-cancers-11-01505]\], BUP1 \[[@B80-cancers-11-01505]\], chromogranin B \[[@B81-cancers-11-01505]\], ERBB2 \[[@B82-cancers-11-01505]\], and/or the well-known SDHB immunohistochemistry \[[@B83-cancers-11-01505]\].

4. Follow-Up {#sec4-cancers-11-01505}
============

It should be emphasized that *all* patients with a history of a PCC/PGL are at risk of recurrence---even after complete (R0) resection---and *any* PCCs/PGL may have metastatic potential \[[@B19-cancers-11-01505],[@B39-cancers-11-01505]\]. This is especially important for those patients with large (≥5--6 cm) tumors \[[@B64-cancers-11-01505]\]. Moreover, extra-adrenal location, a noradrenergic or dopaminergic biochemical phenotype, high chromogranin A levels, young age \<20 years, multiplicity, and, most importantly, pseudohypoxic cluster 1-related germline mutations (especially *SDHA/B*), are associated with a higher metastatic risk and an adverse prognosis once metastasis is found \[[@B16-cancers-11-01505],[@B17-cancers-11-01505],[@B84-cancers-11-01505],[@B85-cancers-11-01505],[@B86-cancers-11-01505],[@B87-cancers-11-01505],[@B88-cancers-11-01505]\].

Furthermore, pathologists cannot safely determine from histological findings if a PCC/PGL is "malignant" or has "metastatic potential" since the existing grading systems \[[@B26-cancers-11-01505],[@B27-cancers-11-01505]\] are of limited predictive power and well-validated biomarkers for metastatic diseases are missing \[[@B19-cancers-11-01505],[@B28-cancers-11-01505],[@B29-cancers-11-01505],[@B39-cancers-11-01505]\]. Thus, for *all* patients with a history of a PCC, follow-up for at least 10 years is suggested \[[@B39-cancers-11-01505],[@B42-cancers-11-01505]\]; for high-risk PCC patients (germline mutation, young age \<20 years, large tumor ≥5--6 cm, for *SDHB* carriers tumor size ≥3--3.5 cm) and *all* PGL patients lifelong surveillance is recommended---at least consisting of a yearly clinical investigation and assessment of urinary or plasma metanephrines and 3-methoxytyramine (see above) \[[@B39-cancers-11-01505],[@B42-cancers-11-01505],[@B88-cancers-11-01505]\]. In cases of biochemically-silent PCCs/PGLs, additional imaging every one--two years is suggested \[[@B39-cancers-11-01505]\]. In order to minimize radiation exposure, MRI is the preferred imaging modality for follow-up but it can miss tumors in unusual locations.

All patients at risk for a new PCC/PGL due to a germline mutation should also be offered lifelong surveillance \[[@B39-cancers-11-01505],[@B88-cancers-11-01505],[@B89-cancers-11-01505]\]. However, currently, the details of such lifelong surveillance are unclear---especially if and how often imaging should be performed. Accordingly, due to the strong inter-patient heterogeneity depending on the underlying germline mutations and disease characteristics, Crona et al. suggest a personalized surveillance program using genetic mutations together with disease characteristics ([Table 3](#cancers-11-01505-t003){ref-type="table"}) \[[@B32-cancers-11-01505],[@B42-cancers-11-01505],[@B89-cancers-11-01505]\].

For *VHL, SDHx,* MEN2, *NF1, TMEM127*, and *MAX*, follow-up recommendations and consensus statements have previously been published \[[@B64-cancers-11-01505],[@B89-cancers-11-01505],[@B91-cancers-11-01505],[@B92-cancers-11-01505],[@B93-cancers-11-01505],[@B94-cancers-11-01505]\].

4.1. Conclusion/Practical Tips {#sec4dot1-cancers-11-01505}
------------------------------

In patients with elevated metanephrines prior to PCC/PGL surgery, plasma/urine metanephrines and 3-methoxytyramine (plasma only) should be assessed on pain-free recovery three--six weeks after surgery \[[@B39-cancers-11-01505]\]; in patients with elevated chromogranin A prior to PCC/PGL surgery, chromogranin A should be assessed three--six weeks after surgery \[[@B39-cancers-11-01505]\]; in the rare patients with non-functional PCC/PGL (no tumoral synthesis of catecholamines) or with postoperatively elevated metaneprines or 3-methoxytyramine, imaging should be performed three--four months after presumed complete surgery (if possible with the recommended radionuclide imaging, see above) \[[@B39-cancers-11-01505]\].

We suggest especially radionuclide imaging three-four months after presumed complete resection of a metastatic/multiple PCC, *any* PGL, or high-risk (*SDHA/B*) mutation carrier in the case of post-operative abnormal biochemistry or non-functional tumor ([Table 3](#cancers-11-01505-t003){ref-type="table"}).

At least 10 years follow-up is recommended for all patients with a history of PCC, but if the tumor was initially ≥5--6 cm, lifelong follow-up is recommended.

Lifelong follow-up is recommended for all high-risk patients (every patient with a germline mutation, PGL, young age \<20 years, large tumor size ≥5--6 cm, for *SDHB* carriers tumor size ≥3--3.5 cm, multiplicity/recurrence, noradrenergic/dopaminergic phenotype at the initial presentation, moderately to poorly differentiated PCC according to the GAPP classification system).

A personalized surveillance program is suggested depending on the underlying germline mutation and disease characteristics ([Table 3](#cancers-11-01505-t003){ref-type="table"}).

For patients with high-risk mutations (especially *SDHA/B*), we suggest clinical/biochemical control every six months and MRI every one--two years (consider CT for suspected lung involvement or use an alternate approach using CT and MRI).

For completely resected metastatic PGL/PCC, we suggest clinical/biochemical control every six months, MRI six months and 12 months after surgery, then annually. CT can be also used, but with more caution and less frequently since it possesses a radiation risk. An alternate approach using CT and MRI is also an option. Additional radionuclide imaging may be considered every two-three years, especially in the case of high-risk mutations (*SDHA/B*). Other risk factors may apply as well, but their validation may be needed.

For staging purposes of metastatic disease, we suggest whole body cross-sectional CT or MRI every four--six months and radionuclide imaging every one--two years depending on whether PRRT is considered as a treatment option; a patient's age and the growth rate/grading of the tumor are also important factors to be considered.

4.2. Perspectives {#sec4dot2-cancers-11-01505}
-----------------

For all above recommendations on follow-up, it should be considered, although it appears logical, that earlier diagnosis of PCC/PGL by follow-up surveillance should provide for better outcomes. This has not been established by any evidence-based study. One recent study provides suggestive evidence for improved outcomes with surveillance in mutation carriers \[[@B95-cancers-11-01505]\], but the retrospective nature of that study and associated uneven matching of populations were confounders that do not allow concrete conclusions about the benefits of follow-up. The international multicenter prospective cohort study PROSPHEO including patients with a history of PCC/PGL, newly-diagnosed PCC/PGL, or mutations in PCC/PGL susceptibility genes from different centers in Germany and Switzerland over 18 years may eventually be able to answer questions concerning benefits of follow-up surveillance as well as the optimal follow-up procedures.

5. Therapy {#sec5-cancers-11-01505}
==========

Surgery is always the therapy of choice of non-metastatic PCC/PGL, whenever possible \[[@B96-cancers-11-01505],[@B97-cancers-11-01505]\]. However, surgery of non-functioning HN PGLs has to be carefully balanced against surgery-related morbidities, especially for the cranial nerves for vagal and jugular PGLs \[[@B98-cancers-11-01505],[@B99-cancers-11-01505]\]. In cases of a high risk related to surgery, radiotherapy/radiosurgery (gamma-knife/cyberknife) might be a less invasive option with non-curative but controlling outcomes \[[@B100-cancers-11-01505],[@B101-cancers-11-01505],[@B102-cancers-11-01505]\].

In patients with hereditary PCCs, cortical sparing surgery should always be considered since there is frequently a high risk of bilateral PCCs in hereditary disease, and cortical-sparing surgery was not associated with decreased survival despite PCC recurrence in 13% of cases in a very recently published study \[[@B103-cancers-11-01505]\].

With metastatic disease, primary tumor resection should be recommended if feasible in order to alleviate cardiovascular and other symptoms from catecholamine excess or from tumor invasion, and to minimize the target for radiopharmaceutical therapies \[[@B31-cancers-11-01505],[@B104-cancers-11-01505],[@B105-cancers-11-01505]\]. Moreover, several studies have shown that surgical resection of the primary tumor is associated with improved survival even with metastatic disease \[[@B104-cancers-11-01505],[@B106-cancers-11-01505],[@B107-cancers-11-01505]\]. In addition, complete metastatic surgery may be considered in oligo-metastatic PCC/PGL on a case-by-case decision, although there is only little evidence for such an approach from single case reports \[[@B108-cancers-11-01505],[@B109-cancers-11-01505]\].

Watchful waiting with frequent follow-up may be the optimal initial approach in patients with non-functioning HN PGL, especially without evidence of significant tumor growth and/or compression of surrounding structures.

Conventional external beam radiation therapy (cEBRT) or radiosurgery (gamma-knife/cyberknife) are well-established methods in the case of bone metastases and also may play a significant palliative role in oligo-metastatic scenarios \[[@B102-cancers-11-01505],[@B110-cancers-11-01505]\].

Minimally-invasive procedures such as radiofrequency ablation, cryoablation, and ethanol injection may be considered in the treatment of metastatic PCC/PGL, especially in oligo-metastatic disease \[[@B111-cancers-11-01505],[@B112-cancers-11-01505]\].

Bisphosphonate or denosumab therapy should be considered in the case of bone metastases by analogy with other types of neuroendocrine tumors.

Adequate blood pressure control with alpha adrenoceptor blockade at least 10--14 days prior to surgery is essential in functioning PCCs/PGLs to prevent severe cardiovascular events during surgery \[[@B12-cancers-11-01505],[@B113-cancers-11-01505],[@B114-cancers-11-01505]\]. In palliative scenarios, alpha adrenoceptor blockade should also be considered---balanced against side effects---to alleviate hormonal symptoms and prevent complications from catecholamine excess \[[@B42-cancers-11-01505]\]. It has been conventional to use phenoxybenzamine at starting doses approximating 10 mg 2--3x per day, although other similar drugs such as doxazosin and prazosin have been used. There is no clear evidence for the superiority of one alpha-blocker for the pre-operative blockade of PCC/PGL patients, as previously reviewed \[[@B115-cancers-11-01505]\]. Nevertheless, perioperative hypertension seems to be slightly better controlled with phenoxybenzamine (especially in those patients with high catecholamine or metanephrine levels), although with more pronounced postoperative hypotension. Indeed, there were fewer side effects in the doxazosin group \[[@B115-cancers-11-01505]\]. Moreover, in functioning metastatic PCCs/PGLs, pre-treatment alpha blockade is recommended prior to initiation of therapy to prevent symptomatic catecholamine release in response to locoregional or systemic treatment. Furthermore, it is important to mention that beta adrenoceptor blockers must not be given prior to initiation of an adequate alpha adrenoceptor blockade \[[@B114-cancers-11-01505]\].

For metastatic PCCs/PGLs, there are few established treatment options but radiotherapy (\[^131^I\]MIBG therapy, recently PRRT) as well as classic chemotherapy (Averbuch scheme, and temozolomide), and different targeted therapy options, have been extensively used outside of controlled clinical trials ([Figure 1](#cancers-11-01505-f001){ref-type="fig"}, modified from \[[@B34-cancers-11-01505]\]) \[[@B34-cancers-11-01505],[@B116-cancers-11-01505]\].

The only officially (FDA)-approved treatment option in the US is high-specific activity (HSA) \[^131^I\]MIBG therapy (Ultratrace) \[[@B117-cancers-11-01505]\].

5.1. Targeted Endoradionuclide Therapy Using \[^131^I\]MIBG or Radiolabeled Somatostatin Analogs (PRRT) {#sec5dot1-cancers-11-01505}
-------------------------------------------------------------------------------------------------------

The best investigated and well established therapy for metastatic PGL/PCC is \[^131^I\]MIBG therapy, which is preferentially recommended for slow-growing \[^123/131^I\]MIBG positive metastatic PCCs/PGLs \[[@B32-cancers-11-01505],[@B34-cancers-11-01505]\], although the studies are very heterogeneous and most are retrospective \[[@B118-cancers-11-01505]\]. In a meta-analysis of 17 studies with 243 PCC/PGL patients on \[^131^I\]MIBG therapy, there was a complete response in 3% of patients, a partial response in 27% of patients and stable disease in 52% of patients: 40% of patients showed a partial hormonal response \[[@B118-cancers-11-01505]\]. In two of these studies, the mean progression-free survival (PFS) of \[^131^I\]MIBG treated patients was 23.1 and 28.5 months, respectively \[[@B118-cancers-11-01505]\]. However, due to the unknown status regarding tumor progression prior to therapy in most of these studies, no conclusion can be drawn from the rated stabilization observed in these studies \[[@B118-cancers-11-01505]\]. One study included patients only after progressive disease, but PFS and overall survival (OS) were not reported in this study \[[@B119-cancers-11-01505]\]. Objective responses were mainly observed in patients with soft tissue metastases with a prolonged PFS, but there was no demonstrated impact on survival \[[@B118-cancers-11-01505]\].

The most common side effects are anorexia, nausea, vomiting, and hematologic toxicity with grade 3--4 neutropenia in 87% of patients and grade 3--4 thrombocytopenia in 83% \[[@B118-cancers-11-01505]\]. However, in long-term survivors there is a risk of myelodysplastic disorders \[[@B120-cancers-11-01505]\]. One problem with conventional \[^131^I\]MIBG therapy is the relatively low specific activity of the radiopharmaceutical (most of the MIBG molecules are not ^131^I-labeled) potentially leading to less uptake into the tumor and life-threatening side-effects. Very recently, high-specific activity (HSA) \[^131^I\]MIBG that consists almost entirely of ^131^I-labeled molecules has been developed \[[@B117-cancers-11-01505]\]. A recent multicentric phase II study led to the FDA-approval of HSA \[^131^I\]MIBG (Ultratrace, *Azedra*) in the United States \[[@B117-cancers-11-01505]\]: 68 patients received at least one and 50/68 patients received two doses of HSA \[^131^I\]MIBG. Of the 68 patients who received at least one therapeutic dose of HSA \[^131^I\]MIBG, 17 (25%) had a durable reduction in baseline anti-hypertensive medication use. Of the 64 patients with evaluable disease, most patients (59/64, 92%) showed partial responses (23%, 15/64) or stable disease (44/64, 69%) as the best objective response. The median OS was 36.7 months (95% confidence interval, 29.9--49.1 months) with 18 months for patients who received one therapeutic dose and 44 months for those who received two therapeutic doses \[[@B117-cancers-11-01505]\]. The most common treatment-related side effects were nausea, myelosuppression, and fatigue \[[@B117-cancers-11-01505]\], with a higher rate of hematologic toxicity compared to conventional \[^131^I\]MIBG-therapy.

Since most PCCs/PGLs strongly express somatostatin receptor subtype 2 (SSTR2) \[[@B121-cancers-11-01505],[@B122-cancers-11-01505]\], PRRT using radiolabeled somatostatin analogs has been studied in several small studies \[[@B123-cancers-11-01505],[@B124-cancers-11-01505],[@B125-cancers-11-01505],[@B126-cancers-11-01505],[@B127-cancers-11-01505],[@B128-cancers-11-01505],[@B129-cancers-11-01505],[@B130-cancers-11-01505],[@B131-cancers-11-01505],[@B132-cancers-11-01505]\] and recently reviewed \[[@B116-cancers-11-01505]\]. Therefore, latterly, PRRT---a treatment option that has already been approved for gastro-enteropancreatic and pulmonary neuroendocrine tumors in many countries \[[@B133-cancers-11-01505]\]---has also been suggested as an effective treatment option for metastatic PCCs/PGLs \[[@B116-cancers-11-01505]\]. PRRT planning is always preceded by somatostatin receptor imaging as part of a theranostic approach. Although most studies consist of small numbers and limited follow-up, in one direct comparison study the percentage of patients with tumors showing disease stabilization was significantly greater after PRRT using \[^177^Lu\]Lu-DOTA(Tyr^3^)octreotate (TATE) (100%) compared to \[^131^I\]MIBG (62.5%), with a longer PFS/OS of 38.5/60.8 months in the \[^177^Lu\]Lu-DOTATATE group versus 20.6/41.2 months in the \[^131^I\]MIBG group \[[@B127-cancers-11-01505]\]. The benefit of \[^177^Lu\]Lu-DOTATATE, compared to \[^131^I\]MIBG, regarding PFS and OS was even stronger in the subgroup of PGLs (PFS/OS \[^177^Lu\]Lu-DOTATATE: 22.8/60.8, PFS/OS \[^131^I\]MIBG: 14.4/38.5) \[[@B127-cancers-11-01505]\]. Further clinically controlled studies (e.g., NCT04029428, NCT03923257, NCT03206060) should be awaited with regard to recommendations and guidelines, including the selection of the radionuclide (^90^Y, ^177^Lu; another potential future option is the use of α-emitting radionuclides \[[@B134-cancers-11-01505]\]), doses and dose regimens, but also the consideration of specific risk constellations (nephrotoxicity, patient age, co-medication with SSA).

Most common treatment-related side effects of PRRT which is already well-studied in neuroendocrine tumors \[[@B133-cancers-11-01505]\] are renal or hematological (bone marrow) toxicities that can be minimized by adequate precautions and proper and safe dosing \[[@B135-cancers-11-01505],[@B136-cancers-11-01505],[@B137-cancers-11-01505],[@B138-cancers-11-01505]\].

In order to maximize radionuclide uptake in the tumor with minimal risk to organs at risk (especially the kidney), an internal patient-specific dosimetry prior to PRRT is a potential future approach (personalized PRRT) \[[@B139-cancers-11-01505],[@B140-cancers-11-01505],[@B141-cancers-11-01505],[@B142-cancers-11-01505]\]. However, currently, a fixed empiric dose is applied in analogy to the NETTER-1 trial in most centers \[[@B133-cancers-11-01505]\] and dosimetry is not a standard procedure.

Interestingly, there are few or no data on the use of unlabeled long-acting somatostatin analogs, such as octreotide LAR or lanreotide autogel, in therapy. These are administered once a month, and in patients with other forms of neuroendocrine tumors (NETs), especially pancreatic and midgut NETs, they cannot only inhibit hormonal secretion but, according to two large-scale trials, attenuate tumor progression \[[@B143-cancers-11-01505],[@B144-cancers-11-01505]\]. As such agents are usually well-tolerated with generally mild adverse effects, they may be trialed in patients with the aim of lowering catecholamine secretion and possibly stabilizing tumor growth, especially when ^68^Ga\[Ga\]-DOTATATE PET/CT is positive.

### Conclusion/Practical Tips

\[^131^I\]MIBG therapy is still recommended for slow-growing metastatic PCC/PGL.

Very recently, HSA \[^131^I\]MIBG (*Azedra*) has been FDA-approved in the United States for the treatment of metastatic PCC/PGL. However, HSA \[^131^I\]MIBG was associated with a higher rate of hematologic toxicity although it can result in long-lasting disease stabilization and it may be preferable in patients with good bone marrow reserve.

One head-to-head comparison study indicates that somatostatin receptor targeted PRRT may be superior to conventional \[^131^I\]MIBG-therapy regarding treatment response, PFS and OS in metastatic PCC/PGL, especially in the subgroup of PGLs, and may be recommended for slow-growing metastatic PCC/PGL.

5.2. Chemotherapy {#sec5dot2-cancers-11-01505}
-----------------

The second most studied therapy recommended for rapidly progressing metastatic PCC/PGL is conventional chemotherapy with cyclophosphamide, vincristine, and dacarbazine (CVD, Averbuch scheme: Cyclophosphamide 750 mg/m^2^, vincristine 1.4 mg/m^2^, and dacarbazine 600 mg/m^2^ on day 1 and dacarbazine 600 mg/m^2^ on day 2, at 21 day intervals) \[[@B145-cancers-11-01505],[@B146-cancers-11-01505]\]. In a meta-analysis of the largest studies, CVD led to a complete response in 4%, a partial response in 37%, and stable disease in 14% of patients \[[@B145-cancers-11-01505]\]. PFS was only reported in two of these studies with 20 and 40 months, respectively. However, due to missing information regarding tumor progression prior to therapy, no valid conclusions can be drawn from these PFS data \[[@B145-cancers-11-01505]\]. There is only one study solely including patients with progression prior to therapy which showed a radiological and clinical response in 33% of patients \[[@B105-cancers-11-01505]\]. This is also the only study showing a significant survival benefit for patients who responded to CVD chemotherapy: There was a significant effect of response to chemotherapy on median OS (according to a multivariate Cox proportional hazard model analyses) \[[@B105-cancers-11-01505]\]. The median OS of radiological responders was 6.4 years versus 3.7 years for non-responders \[[@B105-cancers-11-01505]\]. The CVD regimen has been shown to be especially effective in *SDHB*-related PCC/PGLs \[[@B145-cancers-11-01505],[@B147-cancers-11-01505],[@B148-cancers-11-01505]\].

Prolonged CVD chemotherapy (median of 20.5 cycles) in 12 patients with *SDHB* mutations led to a total response in 83% of patients \[partial response 8/12 (66.7%) patients, complete response 2/12 (16.7%) patients, assessed by Response Evaluation Criteria in Solid Tumors (RECIST)\] and a PFS/OS of 930 and 1190 days, respectively \[[@B148-cancers-11-01505]\]. On a case-by-case basis, prolonged CVD therapy can be considered, especially for metastatic *SDHB*-related PCC/PGLs.

Monotherapy with the DNA-alkylating chemotherapeutic temozolomide, an oral metabolite of dacarbazine, showed a partial response (33%) or stable disease (47%) in a total of 80% of patients with *SDHB* mutations, and thus may be used as a single agent treatment, or alternatively could be considered as a maintenance regime for tumor stabilization subsequent to six--nine cycles of CVD chemotherapy (150 mg/m^2^ on days 1--5, at 28 day intervals) \[[@B149-cancers-11-01505],[@B150-cancers-11-01505]\]. Down-regulation of the DNA repairing enzyme O-6-methylguanine-DNA methyltransferase (MGMT) via hypermethylation in *SDHB* mutated tumors appears to lead to increased susceptibility of *SDHB*-related PCCs/PGLs to temozolomide \[[@B149-cancers-11-01505],[@B151-cancers-11-01505],[@B152-cancers-11-01505],[@B153-cancers-11-01505]\].

In the case of intolerance to temozolomide monotherapy, a combination of a metronomic scheme with long-term low-dose temozolomide (75 mg/m^2^ per day for three weeks followed by one week off treatment) and high-dose lanreotide autogel (120 mg s.c. every 14 days) may be an alternative in order to stabilize PCC/PGL growth (low MGMT levels seem to be beneficial), as reported for two patients \[[@B150-cancers-11-01505]\].

The well-known side effects of CVD chemotherapy include amongst others nausea, vomiting, myelosuppression, peripheral sensory and autonomic neuropathy (vincristine), hemorrhagic cystitis (cyclophosphamide), and infertility \[[@B105-cancers-11-01505],[@B154-cancers-11-01505]\].

Whether adjuvant chemotherapy with four--six cycles of CVD after surgery is beneficial, has not as yet been studied. There are no data providing evidence for adjuvant chemotherapy.

### Conclusion/Practical Tips

CVD chemotherapy (cyclophosphamide 750 mg/m^2^, vincristine 1.4 mg/m^2^, and dacarbazine 600 mg/m^2^ on day 1 and dacarbazine 600 mg/m^2^ on day 2, at 21 day intervals) is recommended for rapidly progressive (\<6 months) metastatic PCC/PGL and especially effective in *SDHB*-related disease.

On a case-by-case decision, prolonged treatment with CVD chemotherapy with 20 cycles of CVD is suggested, especially in the case of patients with *SDHB* mutations.

Alternatively, temozolomide monotherapy (150 mg/m^2^ on days 1--5, at 28 day intervals) or a metronomic scheme with temozolomide (75 mg/m^2^ per day for three weeks followed by one week off treatment) may be considered, either as initial therapy or following stabilization with CVD.

5.3. Targeted Therapy and Immunotherapy {#sec5dot3-cancers-11-01505}
---------------------------------------

Different receptor tyrosine kinase inhibitors (TKIs) (sunitinib, cabozantinib, axitinib, lenvatinib, and pazopanib) are currently under evaluation as treatment options for metastatic PCCs/PGLs. They all have anti-angiogenic effects and may be interesting therapy options for cluster 1 and cluster 2 mutated PCCs/PGLs.

The best studied TKI is sunitinib, which is already approved by the FDA and by the European Medicines Agency (EMA) for pancreatic neuroendocrine tumors, renal cell cancer, and gastrointestinal stromal tumors. Sunitinib leads to inhibition of VEGF1/2 receptors, platelet-derived growth factor-β receptor (PDGFR) and RET. The largest retrospective study included 17 patients of which 14 were evaluable for tumor responses to sunitinib (dose: 37.5 mg or 50 mg) \[[@B155-cancers-11-01505]\]. Of the 14 patients, a total of 8/14 (57%) of the patients showed a partial response (3/14, 21%) or stable disease (5/14, 36%) \[[@B155-cancers-11-01505]\]. However, the median PFS was only 4.1 months, although there was a much longer PFS in the responders compared to the non-responders. The PFS of the three partial responders was 11, 12, and 4.5 months, respectively \[[@B155-cancers-11-01505]\]. The PFS of three patients with stable disease was 27, 8, and 6 months, respectively, and two other patients with stable disease experienced no progression until the end of the observation period (36 months). One of these patients remained on targeted combination therapy with sunitinib and the mTORC1 inhibitor rapamycin for 1.5 years until the end of the observation period \[[@B155-cancers-11-01505]\]. In the non-responders, the PFS was 0.4--4 months. A total of 6/8 (75%) of the patients with stable disease or partial responses in this study were *SDHB* mutation carriers, indicating clinical benefit especially for *SDHB*-related PCCs/PGLs \[[@B155-cancers-11-01505]\].

Importantly, the largest prospective sunitinib phase II multicenter study has recently been published (regime: 50 mg sunitinib daily for four weeks, followed by two weeks off treatment corresponding to one cycle): The total disease control rate (stable disease or partial response) was 83% (95% CI: 61--95%): 3/23 (13%) patients showed a partial response. All responders were carriers of germline mutations (*SDHA, SDHB, RET*). The median PFS was 13.4 (95% CI: 5.3--24.6) months \[[@B156-cancers-11-01505]\]. The *RET*-mutated patient with MEN2A was still on sunitinib therapy by the time the study was published (after 64 cycles) which may implicate that *RET* and *SDHx* mutation carriers as benefiting the most \[[@B156-cancers-11-01505]\].

At present, sunitinib is being investigated in the first randomized placebo-controlled phase II clinical trial in advanced PCC/PGL (FIRST-MAPP, NCT01371202), recruitment (n = 74) has been completed and results are pending.

Common side effects of sunitinib are fatigue, nausea, vomiting, diarrhea, taste changes, heartburn, severe hypertension, and myelosuppression.

Another TKI, the c-Met inhibitor cabozantinib, which was more effective than sunitinib in renal cell carcinoma and in human PCC/PGL primary culture \[[@B157-cancers-11-01505],[@B158-cancers-11-01505],[@B159-cancers-11-01505]\], is currently being investigated in a phase II clinical study in 11 metastatic PCC/PGL patients (initial dose: 60 mg, titrated down on the basis of tolerability) (NCT02302833). Preliminary data have shown tumor size reduction and disease stabilization in most patients, with a median PFS of 11.2 months \[[@B160-cancers-11-01505]\]. The side effects of cabozantinib are similar to those of sunitinib.

The TKI axitinib (AG-013736) is currently being investigated in a phase II non-randomized clinical trial including 14 patients with metatstatic PCC/PGL (NCT01967576). Moreover, another phase II clinical trial is evaluating the efficacy of the TKI lenvatinib, inhibiting VEGFR1/2/3, in advanced PCC/PGL (NCT03008369). The pazopanib trial had to be terminated due to gastrointestinal and severe cardiovascular events \[[@B161-cancers-11-01505]\].

Treatment with the mTORC1 inhibitor everolimus led to disease stabilization in five out of seven patients with advanced PCC/PGL in a small phase II study (NCT01152827) \[[@B162-cancers-11-01505]\], but another study showed no effect of the agent on its own \[[@B163-cancers-11-01505]\]. However, one patient treated with 25 mg sunitinib in combination with 4 mg of the mTORC1 inhibitor rapamycin (as mentioned above) experienced maintained long-term disease control \[[@B155-cancers-11-01505]\]. Accordingly, it is possible that targeted therapies in combination may be more effective at lower doses compared to single treatment approaches.

Consistently, we have already shown in several in vitro and in vivo studies that targeted drug combinations show synergistic anti-tumor effects in PCCs/PGLs \[[@B159-cancers-11-01505],[@B164-cancers-11-01505],[@B165-cancers-11-01505],[@B166-cancers-11-01505],[@B167-cancers-11-01505]\]. Moreover, very recently, we established a method to screen multiple targeted drug combinations---some are already in use for other types of cancers---ex vivo in human PCC/PGL primary cultures of individual patient tumors \[[@B159-cancers-11-01505]\]. These data may then be correlated to the signaling pathway alterations and the individual genetic background of the tumor \[[@B159-cancers-11-01505]\]. This will hopefully pave the way to customized combination therapy to target individual patient tumors.

Potentially interesting novel targeted therapy approaches for PCCs/PGLs (especially cluster 1-related) include HIF-2α inhibitors, inhibitors of the DNA repairing enzyme Poly(ADP-ribose) polymerase (PARP) (especially in combination with temozolomide), histone deacetylase (HDAC) inhibitors, SSTR2 analogs (see above), or DNA demethylating agents (DNA methyltransferase inhibitor SGI-110 is under investigation in a phase II clinical trial for treatment of *SDHx*-related PCCs/PGLs, NCT03165721), as recently reviewed \[[@B34-cancers-11-01505],[@B168-cancers-11-01505]\].

Pseudo-hypoxia may prevent the immune system from recognizing cluster 1-related PCCs/PGLs through inactivation of cytotoxic T-cell lymphocytes, activation of immune-suppressive monocytes and increased expression of the immune checkpoint protein programmed death-ligand 1 (PD-L1) and its receptor \[[@B169-cancers-11-01505],[@B170-cancers-11-01505],[@B171-cancers-11-01505]\]. Therefore, immunotherapy is currently being studied in advanced PCC/PGL in two different phase II clinical studies \[nivolumab plus ipilimumab (NCT02834013) and pembrolizumab (NCT02721732), respectively\].

### Conclusion/Practical Tips

In the case of progression after chemotherapy or radionuclide therapy, or if chemotherapy or radionuclide therapy are not possible/tolerated by the patient, the TKIs sunitinib (37.5 mg or 50 mg daily) or cabozantinib (60 mg daily, or titrated down to a tolerable dose) may be considered, especially for *RET* and *SDHx*-mutation carriers.

Several targeted therapies (PI3K inhibitors in combination with mTORC1 inhibitors, HIF-2α inhibitors, PARP inhibitors, SSTR2 analogs, HDAC inhibitors, DNA demethylating agents) and immunotherapy are currently under investigation and may have strong potential for future personalized therapy approaches.

6. Outlook {#sec6-cancers-11-01505}
==========

Customized combination therapy (targeted therapy combinations \[[@B159-cancers-11-01505]\], combinations of targeted therapy with immunotherapy, or targeted therapy combined with PRRT) to target individual patient tumors depending on their underlying germline/somatic mutation and disease characteristics, are likely to be the future directions of therapeutic options for these fascinating but complex tumors.
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###### 

Pheochromocytomas and paragangliomas (PCC/PGL) characteristics depending on underlying germline/somatic mutations and their clinical presentation and evaluation.

  Genes                                                         *Cluster 1 (Pseudohypoxic Krebs Cycle-Related): SDHx (SDHA, B, C, D, F2), FH, MDH2 (10--15% of PCC/PGL)*   *Cluster 1 (Pseudohypoxia VHL/EPAS1-Related: VHL*, *EPAS1/2* (*HIF2A), PHD1/2 (15--20% of PCC/PGL)*   *Cluster 2 (Kinase Signaling-Related): RET, NF1, MAX, TMEM127, HRAS (50--60% of PCC/PGL)*   *Cluster 3 (Wnt Signaling-Related): CSDE1, MAML3 5--10% of PCC/PGL)*
  ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  Percentage of germline mutations \[[@B2-cancers-11-01505]\]   Germline 100%                                                                                              Germline 25%                                                                                          Germline 20%                                                                                Germline 0%
  Signaling pathways                                            Pseudohypoxia, Krebs cycle-related, HIF-2α stabilization and signaling                                     Pseudohypoxia, *VHL/EPAS1*-related signaling                                                          Kinase signaling: PI3K/AKT, RAS/RAF/ERK, mTORC1/p70S6K                                      Wnt signaling
  Biochemistry                                                  Normetanephrine, 3-methoxytyramine                                                                         Normetanephrine                                                                                       Normetanephrine and metanephrine or metanephrine alone                                      Normetanephrine, metanephrine
  Imaging                                                       \[^68^Ga\]Ga-DOTA-SSA PET/CT (possibly except for *FH*)                                                    \[^18^F\]FDOPA PET/CT (possibly also for *FH*)                                                        \[^18^F\]FDOPA PET/CT in most                                                               Unknown
  Tumor location                                                Mostly extra-adrenal                                                                                       Adrenal, extra-adrenal                                                                                Adrenal                                                                                     Unknown
  Metastatic risk                                               High-Intermediate                                                                                          Intermediate-Low                                                                                      Low                                                                                         Intermediate
  Age of presentation                                           Early (under 20--30 year-old)                                                                              Early, some often during childhood                                                                    Late but some can present early                                                             Unknown
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###### 

Choice of radionuclide imaging based on the underlying germline/somatic mutations and disease characteristics, modified from Taieb et al. \[[@B64-cancers-11-01505]\].

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Radionuclide Imaging Method for Diagnosis, Staging, and Follow-Up   (Sporadic) PGL, Multifocal/Metastatic Disease, *SDHx*   (Sporadic) PCC (Except *SDHx*): *VHL, EPAS1* (*HIF2A*), *FH*, *PHD1/2*, Kinase Signaling-Associated (*NF1, RET, MAX*)
  ------------------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------
  **First choice**                                                    \[^68^Ga\]Ga-DOTA-SSA PET/CT\                           \[^18^F\]FDOPA PET/CT
                                                                      reveals the predictive power for efficacy of PRRT       

  **Second choice**                                                   \[^18^F\]FDG PET/CT\                                    \[^68^Ga\]Ga-DOTA-SSA PET/CT\
                                                                      for *SDHx*-related PGL\                                 (except for *EPAS1* (*HIF2A*), *PHD1/2*)
                                                                      (except for *SDHD*-related HN PGL)                      

  **Second choice**                                                   \[^18^F\]FDOPA PET/CT\                                  \[^18^F\]FDG PET/CT\
                                                                      for *SDHD*-related HN PGL                               for *EPAS1/2* (*HIF2A*), *PHD1/2*
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Follow-up depending on the underlying germline mutation and disease characteristics (after presumably curative surgery).

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Follow-Up                                                                                                              [High Risk Group:]{.ul}\                                                                                                                                                                              [Intermediate Risk Group:]{.ul}\                                                                                                                                                    [Low Risk Group:]{.ul}\
                                                                                                                         Completely Resected Metastatic PCC/PGL, Completely Resected Non-Metastatic Sympathetic PGL, *SDHA*, *SDHB*, *SDHD* (Except for HN PGL), *EPAS1 (HIF2A)*, *PHD1/2*                                     Completely Resected HN PGL, Completely Resected High-Risk PCC, *SDHAF2, SDHC, VHL Type 2, FH* (Data Is Limited), *TMEM127, MAX, RET* (High Risk Allele), Recurrence, Multiplicity   Completely Resected Low-Risk PCC, *VHL* Type 1, *NF1, RET* (Low to Moderate Risk Allele)
  ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------
  **Clinical/metanephrines**                                                                                             6--12 months                                                                                                                                                                                          12 months                                                                                                                                                                           12--24 months

  **Imaging (preferably MRI \*, less frequently CT \*, but an alternate approach is allowed and by some recommended)**   12--24 months (shorter 12-months interval may be based on metastases, the initial size of a tumor, secretory pattern, and young age), consider CT, especially for lung involvement                    24--36 months (36 months applies for small sporadic metanephrine secreting tumors)                                                                                                  Optional at screening

  **Special cases**                                                                                                      Completely resected metastatic PGL/PCC, *SDHA/B* PCC/PGL, sympathetic PGL: May consider radionuclide imaging 3--4 months after surgery if abnormal biochemistry or non-functioning PCC/PGL\                                                                                                                                                                                               
                                                                                                                         Completely resected metastatic PGL/metastatic PCC (independent of biochemistry): MRI 6 months, 12 months after surgery, then MRI yearly, consider specific radionuclide imaging every 24--36 months                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Red letters: Especially high risk; definition of high-risk PCC: Diameter ≥5--6 cm, or ≥3--3.5 cm for *SDHB* carriers, or young age \<20 at diagnosis, or moderately to poorly differentiated PCC according to GAPP classification system, norepinephrine/dopamine hyper-secretion; RET low risk alleles (incidence around 10%): G533C, K666E, L790F, V804L, V804M, S891A; RET moderate risk alleles (incidence 20--30%): C609F/G/R/S/Y, C611F/G/S/Y/W, C618F/R/S, C620F/R/S, C630R/Y; RET high risk alleles (incidence around 50%): M918T, D631Y, C634F/G/R/S/W/Y, A883F \[[@B90-cancers-11-01505]\]; RET low and moderate risk alleles: Begin screening for PCC at the age of 16 years; RET high risk alleles: Begin screening for PCC at the age of 11 years (for all *RET* mutations consider medullary thyroid carcinoma) \[[@B90-cancers-11-01505]\]. \* Whole body MRI/CT (from skull base to pelvis) in the high risk group, consider focused MRI/CT in the intermediate and low risk group (for example no head and neck imaging in *MAX, FH, NF1*).

[^1]: These authors contributed equally to this work.
